Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes

Diabetes Care

Volumn 28, Issue 4, 2005, Pages 844-849

  Van Wijk, Jeroen P H ^a   De Koning, Eelco J P ^b   Cabezas, Manuel Castro ^a,c   Rabelink, Ton J ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHYLOMICRON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FATTY ACID; HYPERGLYCEMIC AGENT; METFORMIN; PLACEBO; ROSIGLITAZONE; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FATTY ACID METABOLISM; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; LOADING TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CHOLESTEROL, HDL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; POSTPRANDIAL PERIOD; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 15944392288     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.4.844     Document Type: Article

References (34)

1. Taskinen MR: Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733-749, 2003
2. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Roll LG, Sacks FM, Hennekens CH: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276:882-888, 1996
3. de Man FH, Castro Cabezas M, van Barlingen HH, Erkelens DW, de Bruin TW: Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: postprandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 26:89-108, 1996
4. Groot PH, van Stiphout WA, Krauss XH, Jansen H, van Tol A, van Ramshorst E, Chin-On S, Hofman A, Cresswell SR, Havekes L: Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 11:653-662, 1991
5. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W: Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb 12:1336-1345, 1992
6. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, Liron M, Rubinstein A, Iaina A: Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ 312:936-939, 1996
7. van Wijk JP, Halkes CJ, De Jaegere PP, Plokker HW, Erkelens DW, Cabezas MC: Normalization of daytime triglyceridemia by simvastatin in fasting normotriglyceridemic patients with premature coronary sclerosis. Atherosclerosis 171:109-116, 2003
8. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A: Postprandial lipoproteins and progression of atherosclerosis. Atherosclerosis 106:83-97, 1994
9. Halkes CJ, van Dijk H, de Jaegere PP, Plokker HW, van der Helm Y, Erkelens DW, Cabezas MC: Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 21:1526-1530, 2001
10. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
11. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956, 1995
12. van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ: Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 23:1744-1749, 2003
13. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219, 2001
14. Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H, Miyashita Y: The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 46:35-41, 1999
15. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J: PPARalpha and PPAR-gamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15:5336-5348, 1996
16. Verseyden C, Meijssen S, Castro Cabezas M: Postprandial changes of apoB-100 and apoB-48 in triglycerides rich lipoproteins in familial combined hyperlipidemia. J Lipid Res 43:274-280, 2002
17. Karpe F, Hamsten A: Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J Lipid Res 35:1311-1317, 1994
18. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24:930-934, 2004
19. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818-1820, 1998
20. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86:3452-3456, 2001
21. Shimono D, Kuwamura N, Nakamura Y, Koshiyama H: Lack of effect of pioglitazone on postprandial triglyceride levels in type 2 diabetes. Diabetes Care 24:971, 2001
22. Karpe F: Postprandial lipemia: effect of lipid-lowering drugs. Atheroscler Suppl 3: 41-46, 2002
23. Gauthier A, Vassiliou G, Benoist F, McPherson R: Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. J Biol Chem 278:11945-11953, 2003
24. Rieusset J, Auwerx J, Vidal H: Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 265:265-271, 1999
25. Bogacka I, Xie H, Bray GA, Smith SR: The effect of pioglitazone on peroxisome proliferators-activated receptor-γ target genes related to lipid storage in vivo. Diabetes Care 27:1660-1667, 2004
26. Spiegelman BM: PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998
27. Jeppesen J, Zhou MY, Chen YD, Reaven GM: Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 17: 1093-1099, 1994
28. Jeppesen J, Zhou MY, Chen YD, Reaven GM: Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM. Diabetoiogia 37:781-787, 1994
29. Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR: Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 18:484-490, 2002
30. Karpe F, Hultin M: Endogenous triglyceride-rich lipoproteins accumulate in rat plasma when competing with a chylomicron-like triglyceride emulsion for a common lipolytic pathway. J Lipid Res 36: 1557-1566, 1995
31. Malmstrom R, Packard CJ, Watson TD, Rannikko S, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen MR: Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17: 1454-1464, 1997
32. Prinsen BH, Romijn JA, Bisschop PH, de Barse MM, Barrett PH, Ackermans M, Berger R, Rabelink TJ, de Sain-van der Velden MG: Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans. J Lipid Res 44:1341-1348, 2003
33. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35:367-372, 2002
34. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38:1008-1017, 2003